R
Richard O. Snyder
Researcher at University of Florida
Publications - 60
Citations - 5725
Richard O. Snyder is an academic researcher from University of Florida. The author has contributed to research in topics: Adeno-associated virus & Viral vector. The author has an hindex of 35, co-authored 59 publications receiving 5437 citations. Previous affiliations of Richard O. Snyder include French Institute of Health and Medical Research & University of Nantes.
Papers
More filters
Journal ArticleDOI
Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
Richard O. Snyder,Carol H. Miao,Gijsbert A. Patijn,S. K. Spratt,Olivier Danos,D Nagy,Allen M. Gown,Brian Winther,Leonard Meuse,L. K. Cohen,Arthur R. Thompson,Mark A. Kay +11 more
TL;DR: It is demonstrated that persistent, curative concentrations of functional human factor IX can be achieved using wild-type-free and adenovirus-free rAAV vectors and demonstrates the potential of treating haemophilia B by gene therapy at the natural site of factor IX production.
Journal ArticleDOI
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors.
Sergei Zolotukhin,Mark Potter,Irene Zolotukhin,Yoshihisa Sakai,Scott A. Loiler,Thomas J. Fraites,Vince A. Chiodo,Tina Phillipsberg,Nicholas Muzyczka,William W. Hauswirth,Terance R Flotte,Barry J. Byrne,Richard O. Snyder +12 more
TL;DR: Reagents and methods for the production and purification of AAV2 inverted terminal repeat-containing vectors pseudotyped with AAV1 or AAV5 capsids are described.
Journal ArticleDOI
Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
Richard O. Snyder,Carol H. Miao,Leonard Meuse,Julie Tubb,Brian A. Donahue,Hui Feng Lin,Darrel W. Stafford,Salil Patel,Arthur R. Thompson,Timothy C. Nichols,Marjorie S. Read,Dwight A. Bellinger,Kenneth M. Brinkhous,Mark A. Kay +13 more
TL;DR: Constitutive expression of factor IX was observed, which resulted in the correction of the bleeding disorder over a period of over 17 months in mice, and as a preclinical model for gene therapy, recombinant adeno-associated viral vectors containing the human or canine factor IX cDNAs were infused into the livers of murine and canine models of hemophilia B.
Journal ArticleDOI
Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats
TL;DR: Data indicate that the use of rAAV, a noncytopathic viral vector, can promote delivery of functional levels of GDNF in a degenerative model of Parkinson's disease.
Journal ArticleDOI
Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure
Marina Moskalenko,Lili Chen,Melinda Van Roey,Brian A. Donahue,Richard O. Snyder,James G. McArthur,Salil D. Patel +6 more
TL;DR: Recombinant adeno-associated virus type 2 (AAV) is a common vector used in human gene therapy protocols and a subset of six peptides which potentially reconstitute a single neutralizing epitope are identified, which may allow the design of reverse genetic approaches to circumvent the preexisting immunity that can be encountered in some individuals.